TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sino Biopharmaceutical ( (HK:1177) ) just unveiled an announcement.
Sino Biopharmaceutical Limited has received approval from both the China National Medical Products Administration and the United States Food and Drug Administration for the clinical trial of its innovative drug, TQF3250, an orally administered GLP-1 receptor agonist intended for weight loss. This development is significant as it offers a more convenient oral alternative to injectable GLP-1 drugs, potentially improving patient adherence and reducing side effects. The approval also extends to the treatment of Type 2 diabetes, aligning with the company’s focus on addressing metabolic diseases and expanding its treatment offerings.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs, particularly in the field of metabolic diseases. The company aims to provide a diverse range of treatment options for patients through its robust pipeline of products.
Average Trading Volume: 101,096,195
Technical Sentiment Signal: Buy
Current Market Cap: HK$123.6B
For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.